Monjuvi's FDA-backed role in follicular lymphoma explained

Monjuvi is now part of a U.S. treatment option for follicular lymphoma after the FDA cleared a new combination use in June 2025, widening its clinical role.

Monjuvi is a lymphoma drug used in the United States, and the FDA approved a new combination use in June 2025 for adults with relapsed or refractory follicular lymphoma OpenPR, 06/2025. That keeps Monjuvi relevant for cancer care teams that need non-chemotherapy options built around targeted therapy.

As of: 05/21/2026 | Reading time: approx. 6 minutes

By the AD HOC NEWS editorial team - specialized in product-focused market coverage.

At a Glance

• Product: Monjuvi
• Category: Prescription oncology medicine
• Brand/Manufacturer: MorphoSys
• Primary Use Cases: Treatment of certain blood cancers, including follicular lymphoma
• Availability: Available in the United States
• Core Markets: United States and select global oncology markets

What Monjuvi Is and How It Works

Monjuvi is the brand name for tafasitamab-cxix, a lab-made antibody designed to attach to CD19 on B cells. In oncology practice, that makes it a targeted therapy rather than a broad chemotherapy drug, which matters for patients whose disease needs a more specific approach OpenPR, 06/2025.

The most important recent shift is its expanded FDA-backed role in follicular lymphoma. That approval broadens how U.S. clinicians can think about Monjuvi in relapsed or refractory disease, where treatment sequencing often depends on prior therapies and patient tolerance OpenPR, 06/2025.

Why Monjuvi Matters for US Patients and Care Teams

For U.S. patients, Monjuvi matters because follicular lymphoma is a chronic blood cancer that can return after earlier treatment. A drug with an approved combination use can give oncologists another option when they are trying to balance response, safety, and convenience OpenPR, 06/2025.

It also fits a broader U.S. trend toward more targeted cancer medicines. That can matter in community oncology settings, where physicians often look for therapies that can be integrated into existing care pathways without requiring fully new treatment infrastructure.

Monjuvi in the US Market and Beyond

Monjuvi remains most relevant in the United States because the FDA approval directly shapes prescribing and reimbursement discussions. For a specialty drug, that regulatory backing is often more important than broad consumer awareness OpenPR, 06/2025.

Outside the U.S., Monjuvi sits in the global oncology market as part of the same targeted-treatment shift. Its commercial relevance depends on physician adoption, label breadth, and how well it fits into existing lymphoma treatment sequences.

• Targeted antibody therapy for B-cell cancers
• Used in oncology settings, not routine retail use
• Relevant for relapsed or refractory lymphoma care
• Important to U.S. cancer specialists and treatment centers

Frequently Asked Questions About Monjuvi

What is Monjuvi used for?
Monjuvi is used in certain blood cancers, including follicular lymphoma, after the FDA approved a new combination use in June 2025 OpenPR, 06/2025.

Is Monjuvi a chemotherapy drug?
No. Monjuvi is a targeted antibody therapy that works by binding to CD19 on B cells.

Why does the FDA decision matter?
It expands the U.S. treatment role for Monjuvi and gives oncologists another approved option for a difficult-to-treat cancer.

Monjuvi is associated with MorphoSys, the company behind the drug's development and commercialization. The product remains a specialized oncology asset rather than a mass-market medicine.

MorphoSys is linked to Monjuvi in Germany. The ISIN provided, DE0006632003, does not validate here, so it is left out of the metadata field.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.